Yeshiva University, Cardozo School of Law

LARC @ Cardozo Law
Online Publications

Faculty

Fall 2017

Wearables and Warranties
Rachel Landy
Jennifer M. Halbleib

Follow this and additional works at: https://larc.cardozo.yu.edu/faculty-online-pubs
Part of the Business Organizations Law Commons, Consumer Protection Law Commons, and the
Contracts Commons

DIGITAL HEALTH REPORT
FALL 2017

Introduction
Driven by the convergence between
healthcare, genomics, and digital
technologies, digital health is a
fast-growing sector with important
implications for individuals to institutions,
alike. Whether its hospitals and health
systems using electronic medical record
management and outcomes metrics to
improve care, parents using wearables
to monitor children with diabetes, or
harnessing precision medicine to design
therapies to attack specific tumors, the
digital health industry represents a market
that is poised for exponential growth.
WSGR is pleased to share our initial
Digital Health Report, which is aimed
at providing digital health participants
with timely insight and updates on
trending topics and the many novel and
intertwined legal and business issues that
permeate this exciting and growing field.
We’d appreciate your feedback on our
report, especially if you have suggestions
on topics you’d like us to consider for
future issues. If you have any comments
or questions, please contact your existing
WSGR attorney(s) or any of the attorneys
listed as authors in our report.
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2017 Is Already the Biggest Year
Ever for Digital Health Investment

Source: Rock Health Funding Research, Q3 2017 1

By Andrew Ellis
If you regularly follow innovation in the
healthcare industry, it is no surprise that
digital health investing has been strong
since 2014. According to data from Rock
Health, investment in digital health more
than doubled to $4.4 billion in 2014 from
just $2.1 billion in 2013. Investments
remained at similar levels for the next
two years, logging $4.6 billion and $4.3
billion in 2015 and 2016.1 Startup Health,
another digital health organization that
tracks venture funding in the sector, uses
a broader definition of digital health and
recorded nearly double the amount of

investment, but shows the same trend
from 2014 through 2016.2
Digital health has continued to strengthen
in 2017. Rock Health and Startup Health
data through Q3 2017 shows that 2017
has already reached $4.7 billion and
$9.0 billion, respectively, exceeding any
prior year of digital health investing. In
addition, 2017 is also on pace to exceed
the number of digital health funding deals
in 2016, according to data from both
providers.
In comparison, although venture
investing in all industries is on pace

1 See: https://rockhealth.com/reports/in-biggest-year-of-digital-health-funding-women-ceos-emerge-asq3-2017-winners/?utm_source=Rock+Weekly&utm_campaign=937afff9ab-Rock_Weekly_10_2&utm_
medium=email&utm_term=0_e44ef774d4-937afff9ab-90916197&mc_cid=937afff9ab&mc_eid=f0877c04a2.
2 See: https://www.startuphealth.com/marketing/insights/51631.

(Continued on page 2)
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2017 Is Already the Biggest Year Ever . . . (continued from page 1)
to beat 2016 levels, according to the
PricewaterhouseCoopers MoneyTree
Report,3 with approximately $55 billion
invested through Q3 2017, compared
with approximately $60 million for all
of 2016, it has not already exceeded
full-year 2016 levels. This demonstrates
that digital health investing is not merely
riding the general venture investment
wave, but is showing unique growth in
the current environment. We are excited
and encouraged by the confidence that
investors continue to show in digital health
and believe there are a few notable trends
that are important.
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Regulatory Environment

The Digital Health Innovation Plan:

Digital Health Megadeals

Even more impressive than the
numbers is the environment in which
these investments took place. With a
new president and multiple attempts
by Congress to repeal or modify key
components of the Affordable Care Act,
2017 has been an uncertain healthcare
environment to say the least.

• 	 Introduces a new paradigm for digital
health regulatory review, demonstrating
a developer-centric approach rather
than a product-centric approach.
This may allow certain developers
to “pre-certify” their product based
on historical quality measures and
market such products with little or no
regulatory review.

As the aggregate amount of digital health
investment has grown, so has the size of
investments. According to Rock Health,
there were three digital health investments
of $100 million or more in 2016,6 but
2017 has already claimed eight such
investments. Startup Health shows a slight
decline in early-stage funding deals with
a sharp increase in Series C and D deals,
adding that Q3 2017 had more mid-stage
and late-stage funding deals than any
other Q3 on record. In addition, Startup
Health shows an increased average round
size from approximately $15 million to
approximately $18 million in 2016 and
year-to-date 2017.

The resilience of digital health investment
in an uncertain regulatory environment is
notable, but the regulatory environment
may be improving. In general, certainty
may be higher in the near and
intermediate terms as Congress appears
ready to turn away from healthcare in
order to focus on tax reform and other
items on the agenda. More specifically, the
passage of the 21st Century Cures Act in
December 20164 laid the groundwork for
digital health regulatory reform measures,
and the first material step in that direction
has come in the form of the Digital Health
Innovation Plan, which was announced on
July 27, 2017.5

• 	 Promises forthcoming guidance
on matters such as mobile medical
applications, medical data, and
medical image storage and retrieval
software, and clinical decision support
software. With the overarching goal
of reducing regulatory burdens on the
fast-moving digital health industry,
these measures may have a positive
effect on the regulatory environment
that would embolden additional
investment in the rest of 2017 and
beyond.

There may be multiple reasons for the
emergence of the digital health megadeal.
First, it may simply reflect confidence
in the long-term value of digital health,
the ability of the FDA to streamline
regulatory processes, and the current
positive economic macroenvironment.
Second, it may simply indicate a maturing

3 See: https://www.pwc.com/us/en/technology/moneytree/explorer.html#/.
4 See our WSGR Alert on the 21st Century Cures Act: https://www.wsgr.com/WSGR/Display.aspx?SectionName=publications/PDFSearch/wsgralert-21st-centurycures-act.htm.
5 See: https://www.fda.gov/downloads/MedicalDevices/DigitalHealth/UCM568735.pdf.
6 See: https://rockhealth.com/reports/2016-year-end-funding-report-a-reality-check-for-digital-health/.
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However, there is a
silver lining in these
numbers. First, because
$38M
of the rising number of
digital health megadeals
$25M
raising private funds,
there are more mature
digital health companies
$13M
with high valuations that
may make attractive
$0M
IPO candidates or may
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attract large buyouts in
future years. Second,
Source: Startup Health Insights, Q3 2017
continued investment
in digital health despite
industry, where the winners have been
the declining number of M&A and IPO
identified, and investors are focusing their
transactions may indicate a longer-term
investment dollars. Third, it may actually
investor focus, which is yet another sign
be a side effect of relatively few exits for
of maturity for the digital health space that
digital health companies in 2017, forcing
helps create stability.
investors to create enough runway for
these companies to continue operations
A Shift from B2C to B2B
rather than seek an exit.
Rock Health recently published an
Where Are the Exits?
interesting survey of 85 digital health
entrepreneurs regarding business-toRock Health reports a multi-year
consumer (B2C) and business-to-business
downtrend in the number of M&A
Funding ($M)

$50M

(B2B) business models.7 Thirty-four
percent of the businesses they surveyed
started out with B2C business models,
and 61 percent of those eventually
changed their business model to either
B2B2C (a hybrid model of B2B and B2C)
or B2B. Only 14 percent of the companies
that Rock Health surveyed still employed
a B2C business model. The largest
investments of 2017 so far also reflect
a B2B focus, as evidenced by the chart
below.
Why does this business model change
affect investment trends? One of the
downsides of a B2C business model in
digital health has always been that it is
a crowded space, and from the results
of the Rock Health survey, it appears
that B2B is also becoming increasingly
crowded. When any space becomes
crowded, the increased competition
can have a negative effect on revenue
and sales cycles, but this effect may
be especially pronounced in digital
health given the long B2B sales and
implementation cycles in the healthcare
space.

transactions in digital health, with 146
digital health deals reported at the close of
Q3 2015 versus 112 and 83 through Q3
2016 and Q3 2017, respectively. Because
so many of these transactions do not
publicly disclose the acquisition price—in
Q3, only 16 out of 83 had a disclosed
transaction amount—it is difficult to
determine the full meaning of these
reduced numbers.

The reduced number of M&A transactions
has not been alleviated by IPO activity in
2017. There were six digital health IPOs in
2015, three in 2016, and none through Q3
2017. In fact, according to Rock Health,
2017 may be the first year since 2012
without a digital health IPO, even though
several digital health companies like
iRhythm, Teladoc, and Tabula Rasa have
performed quite well since their IPOs.

Source: Rock Health Funding Research, Q3 2017

7 See: https://rockhealth.com/reports/streamlining-enterprise-sales-in-digital-health/.
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2017 Is Already the Biggest Year Ever . . . (continued from page 3)
Several WSGR clients have reported
that, while a target company or hospital
may find their product attractive, they
simply do not have the bandwidth in their
infrastructure to onboard multiple digital
health solutions in a given year. Until the
digital health industry matures into a phase
of consolidation, the fragmented nature
of digital health solutions may exacerbate
these infrastructure limitations and delay
revenue from new customers, as more
companies enter the B2B space.

What’s Next?
There are a lot of things to be excited
about in digital health. The industry
appears to be maturing, as evidenced by
more later-stage investments and larger
deal sizes. The regulatory and economic
macroenvironment, while imperfect, looks
favorable at this time. Several high-profile
recent digital health IPOs are performing
well in the public markets. Most
importantly, the fact that aggregate digital
health investment in 2017 has already

exceeded 2016 is an encouraging vote of
confidence by investors.
However, despite the strong numbers,
there are some headwinds: M&A and IPO
activity have trended down since 2015,
and Q3 investment amounts were less
than the very large Q2 numbers. It remains
to be seen whether the strength of 2017
will continue to build momentum into 2018
or will prove to be short-lived, but there is
ample evidence to support an optimistic
view.

Patent and Trade Secret Protection in Digital Health
• 	 Is the subject of efforts that are
reasonable under the circumstances to
maintain its secrecy

By Ali R. Alemozafar and
Charles T. Graves
Practically all digital health companies
are founded on the basis of ideas. For
example, your company may have several
ideas around a smart watch datacollecting sensor that tracks heart rate
using algorithm software. The software
draws correlations from the data as
an actionable output. Such ideas are
often subject to patent and trade secret
protection, which is a key part of enabling
continued growth for your company,
including investment and downstream
acquisition.
Understanding what warrants patent
and trade secret protection is important.
Additionally, selecting the kind of
protection that is right for you is a careful
balance between several considerations.
Below are some frequently asked
questions to provide you with guidance
along the way.
What Is a Patent?
A patent is a government right that
excludes others from practicing the
patented invention for a period of 20
years, creating a limited monopoly. To

There are many famous examples of
ideas that have been maintained as
trade secrets, such as the formula for
Coca-Cola. The term of a trade secret
is theoretically indefinite so long as the
underlying ideas remain secret.

be granted a patent, the ideas being
patented need to be disclosed in a patent
application in sufficient detail to permit
the skilled person reading the patent to
practice the patented invention. This often
requires disclosing certain details of the
secret sauce.
What Is a Trade Secret?
A trade secret is generally information,
including a formula, pattern, compilation,
program, device, method, technique, or
process that both:
• 	 Derives independent economic value,
actual or potential, from not being
generally known to the public and
others who can obtain economic value
from its disclosure or use
4

Which Ideas Are Suitable for Trade
Secret Protection?
A company may pursue trade secret
protection for ideas that can be effectively
kept a secret. The company should
establish an internal policy to maintain
secrecy. Trade secret protection may
enable the company to keep its ideas a
secret and maintain first-mover advantage,
which may be important in an uncrowded
segment of digital health.
Trade secret protection may not be
suitable if the ideas are subject to
publication, may be readily reverseengineered, or derived independently by
another company in a fast moving area of
digital health.
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What Is the Duration of Trade Secret
Protection Versus Patent Protection?
Trade secret protection is indefinite but
thin, while patent protection is time-limited
but thick. However, if an idea that is
maintained as a trade secret is developed
independently by a competitor, made
public, or is reverse-engineered, then the
trade secret protection may no longer be
available.
On the other hand, while the period
for patent protection is limited to 20
years, the patent may be used to stop a
competitor from practicing the invention
covered by the patent, regardless of
whether the competitor independently
derives the invention.
When Would It Make Sense to Pursue
Patent Protection?
Ideas that are generally difficult to protect
under trade secrecy may be better suited
for patent protection. For example, if an
idea may be readily reverse-engineered
or derived independently, then patent
protection may be the more suitable type
of protection.
What Are the Benefits of Pursing a
Patent?
A patent may protect ideas regardless
of whether such ideas are subsequently
reverse-engineered or derived
independently by others. In addition, a
patent may enable a third party, such as
an investor or acquirer, to place concrete
value on a company’s ideas. This may
be important for early-stage companies
seeking financing.
With a trade secret, such value may be
more difficult to show, given that the
value of a trade secret is based on the
underlying ideas not being generally
known to the public or others.
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Factors to Consider When Pursuing Patent or Trade Secret Protection
Patent
Subject Matter

Legal Threshold

Term

Trade Secret

Process, machine, manufacture, or
composition of matter

Information, including a formula,
pattern, compilation, program, device,
method, technique, or process

Right subject matter, new, and
non-obvious

Reasonable efforts to maintain secrecy

20 years

Indefinite

Protect ideas regardless of
reverse-engineering or independent
derivation by others

Upside

Allows third parties to place concrete
value on ideas
Patent application typically published
and reviewed with no guarantee of a
patent

Risk

What Are the Risks When Pursuing
Patent Protection?
To be granted a patent, the idea being
patented needs to be disclosed in a
patent application, which is filed with a
patent office and typically published. The
patent application is reviewed by the
patent office to determine whether the
idea being patented meets a requisite
legal threshold, including whether the idea
is the right subject matter, new, and nonobvious.
An idea directed to a process, machine,
manufacture, or composition of matter
may be the right subject matter for
a patent. This review may involve a
technically and legally intensive negotiation
process with the patent office, called
patent prosecution.
Some ideas are more difficult to patent
than others. For instance, ideas around
algorithms or health data are generally
more difficult to patent than ideas around
hardware. If the patent office finds that an
invention being patented is directed to an
abstract idea, a law of nature, or a natural

5

Keep ideas a secret and maintain
first-mover advantage

Ideas reverse-engineered, derived
independently, or made public
Difficult to place concrete value on ideas

phenomenon, then they may find that it is
not directed to the right subject matter for
a patent.
There is no guarantee that a patent will
be granted from a patent application. A
risk with pursuing patent protection is that
a patent application can be made public
without giving the company any patent
protection. In this circumstance, the ideas
in the patent application will be dedicated
to the public.
Can You Take a Hybrid Approach and
Pursue Both Trade Secret and Patent
Protection?
A company may keep certain aspects
of its technology as a trade secret, while
pursuing patent protection around others.
For example, a digital health company has
software with a particular machine learning
algorithm and a sensor for collecting data.
The company may keep the machine
learning algorithm as a trade secret and
pursue patent protection around the
sensor.
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Wearables and Warranties
By Rachel Landy and Jennifer M.
Halbleib

manufacturer warrants against defects in
materials and workmanship of the product
in its original packaging, but only when the
product is used normally for its intended
purpose. Any warranty also will include
information on how to submit a claim
and the consumer’s remedy, if there is a
defect.
Legal Framework for Warranties

The last few years have seen an explosion
of wearable digital health products.
Where a doctor’s visit used to be required
for a basic check-up, now a patient’s
health status is increasingly at his or her
fingertips. We have the ability to track
fitness levels, monitor lung and heart
capacity, check skin temperature, and
observe blood pressure with a simple
wearable device.
Product warranties give consumers
confidence that these devices will perform
as expected. But overzealous marketing
can also be interpreted as implied
warranties that the manufacturer never
intended, which expose the manufacturer
to potentially significant liability. This is
especially the case with devices used to
track disease or improve health. Liability
may arise under a number of theories,
including false or deceptive advertising, as
well as under warranty law.
ABCs of Express Warranties
Consumer wearables are often
accompanied by express warranties—
promises made by the manufacturer
or retailer to the consumer about the
functionality of a wearable device. For
example, a warranty may state that the

In drafting a consumer warranty, it is
important to keep in mind the basic
legal framework. Consumer warranties
are governed at the federal level by the
Magnuson Moss Warranty Act (MMWA).
Notably, the MMWA does not require that
a warranty be provided with a consumer
product. Instead, it sets forth certain
requirements for any written warranty that
is provided including:
• 	 A description of the product that
is covered, and any parts that are
excluded (e.g., any thirdparty batteries)
• 	 The remedy in the event of a breach of
warranty and who bears which costs
(e.g., the cost of shipping the product
back to the warrantor)
• 	 The effective date of the warranty (e.g.,
the date a product is purchased from
an authorized retailer)
• 	 How long the warranty lasts (e.g., 5
years from purchase)
• 	 A prohibition on disclaiming certain
implied warranties
Some states have additional statutes
that supplement the MMWA. If you are
contemplating business in a specific
state, it is important to review any
relevant state statute. For example,
California’s Song-Beverly Act includes
terms that apply specifically to health
devices. Under the Song-Beverly Act,
“assistive devices”, intended to assist
consumers with physical disability, injury,
or disease treatment are subject to
more strict warranty requirements. For
instance, warrantors of most types of
assistive devices must adhere to specific
replacement terms in the event of a
defect.
6

Marketing Missteps: Unintended
Implied Warranties
In addition to express warranties,
warranties can be implied by the official
product description or marketing. It
can be easy to inadvertently run afoul
of the warranty statutes by making
claims in marketing materials that look
like warranties or promises as to how a
device will work, but are simply intended
to be promotional. For example, in 2015,
a group of consumers brought a class
action suit against Fitbit, alleging that
Fitbit’s marketing of its sleep-tracking
functionality—which included promises
about specific results—breached the
implied warranty of merchantability
under the MMWA, and also constituted
deceptive and unfair trade practices,
among other things. The plaintiffs argued
that the messaging in Fitbit’s product
packaging did not accurately reflect the
device’s capabilities. All claims survived
a motion to dismiss last year and the
litigation is ongoing. Similarly, in 2015,
Nike settled a class action alleging similar
claims against its FuelBand product,
including the product’s inability to
accurately track calories and steps.
Best Practices
When bringing a product to market, it
is important to consider the following
to avoid claims that the MMWA or any
related state laws were violated:
• 	 Ensure that any warranty is drafted in
compliance with the MMWA and any
relevant state statute(s)
• 	 Disclaim accuracies of any specific
results in end user license agreements
• 	 Review marketing and promotional
materials carefully to make sure the
language does not imply any promises
as to effectiveness of a device
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The 21st Century Cures Act:
Clinical Decision Support Software Regulation
By David Hoffmeister and Charles
Andres1
The sophistication and importance
of software intended for use in the
medical field and in medical applications
continues to grow at a dizzying pace.
For example, a robot surgeon in Italy
successfully performed an unassisted
50-minute surgery to treat a patient with
atrial fibrillation, a heart condition.2 The
robot’s software contained data from
about 10,000 real-world surgeries, and
before operating solo, the robot previously
performed assisted procedures on at least
40 people.3 Specialized software running
surgical robots represents just one area of
this growth.
Another essential area is diagnostic
software, which can make diagnoses
independently of a healthcare provider
or act as a diagnostic aid to providers.
ARK Investment Management estimates
that the total global addressable market
for diagnostic software could reach $16
billion.4 With so much at stake, both in
terms of patient outcomes and market
share, all software developers–including
diagnostic software developers–should
understand how medical software is
regulated in the United States.
The U.S. Food and Drug Administration
(FDA) has the authority to regulate
some software as a medical device. It
is important for developers to know if
their software meets the definition of a

medical device, how it will be regulated,
and whether regulatory approval or
clearance is required before it can be
commercialized.5,6
Background on the Act
The 21st Century Cures Act was signed
into law on December 13, 2016.7 Section
3060 of the act amends the Federal
Food, Drug, and Cosmetic Act (FDCA)
to exclude certain software from the
definition of a medical device. This is
important because the excluded software–
so long as certain conditions are met–is
exempt from FDA regulation, creating a
faster and more certain path to market.
Clinical decision support software (CDSS)
is one of these exclusions.
CDSS Exclusion
CDSS can aid healthcare professionals
in making diagnoses. Providers, like
radiologists, who make diagnoses based
on images face several difficulties. They
need to review images from potentially
hundreds of patients daily and often in
stressful settings such as an emergency
room, which may create decision fatigue.
Additionally, image blur and regions of
overlapping tissues can contribute to
incorrect diagnostic decisions. These
factors and others can cause healthcare
professionals to order unnecessary
medical procedures, such as a skin biopsy
for a lesion that turns out to be noncancerous. This exposes the patient to
increased medical risks and increases the

cost burden on healthcare payers.
Section 3060 of the act,8 which is relevant
to CDSS, recites in part that the definition
of medical device shall not include
software for the purpose of:
(i) . . . Analyzing . . . medical information
about a patient . . .; and
(ii) Supporting or providing
recommendations to a healthcare
professional about prevention,
diagnosis, or treatment of a disease or
condition; and
(iii) Enabling such healthcare professional
to independently review the basis
for such recommendations that
such software presents so that it is
not the intent that such healthcare
professional rely primarily on any of
such recommendations to make a
clinical diagnosis or treatment decision
regarding an individual patient.
If the CDSS meets the criteria in
Section 3060, the CDSS has a statutory
safe harbor, with the FDA not having
jurisdiction to regulate it.
It is crucial to note that there are two
broad situations, or exclusions, where
CDSS can nevertheless be regulated by
the FDA as a medical device. The first is
where software “is intended to acquire,
process, or analyze a medial image or
signal from an in vitro diagnostic device or

1 The information herein is provided for informational purposes only and should not be taken as legal advice. Legal counsel should be consulted for questions regarding the regulation of software as a medical device and the 21st Century Cures Act.
2E
 van Blass, “Robot surgeon performs world’s first unassisted operation,” Engadget. See: https://www.engadget.com/2006/05/19/robot-surgeon-performs-worlds-first-unassisted-operation/.
3 Id.
4 James Wang, “Deep Learning Based Diagnostics: Unlocking a $16 Billion Market,” ARK Invest, December 22, 2016. See: https://ark-invest.com/research/
deep-learning-based-diagnostics.
5 In the case of robot surgeons, a company may need to get separate clearance or approval for both the hardware (e.g., the robot) and the software running the robot.
6 Mobile medical application developers should also be familiar with the FDA’s regulatory framework for mobile medical applications. The FDA issued a Mobile Medical
Applications guidance in 2015. The definition of medical device in the guidance is outdated, so the guidance should be consulted with caution.
7 Pub. Law. No. 114-255.
8 21 U.S.C. § 360j(o)(1)(E).

Continued on page 8...
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The 21st Century Cures Act . . . (continued from page 7)
a pattern or signal from a signal acquisition
system.”9 For example, software that
makes diagnostic recommendations
based on the analysis of a medical image
(e.g., CT, radiographs, or MRI) would
not be entitled to the Section 3060 safe
harbor. Rather, these CDSS products
would require approval or clearance by the
FDA.

(i) The Secretary makes a finding that
use of such software function would
be reasonably likely to have serious
adverse health consequences if it does
not operate as intended; and

The second exclusion, where the FDA
can regulate and take the CDSS of the
regulatory safe harbor, includes the
following:

To meet the criteria above, various factors
are required to be considered, and certain
procedural due process requirements
must be adhered to.11

(ii) The software function has been
identified in a final order issued by the
Secretary under subparagraph (B).10

Summary
CDSS will play an increasingly important
role in the day-to-day practice of
medicine. Developers of CDSS should
understand how their CDSS will, or will
not, be regulated by the FDA. Consulting
early with regulatory counsel can help
clarify the regulatory status of CDSS
products.

9 Id.
10 2
 1 U.S.C. § 360j(o)(3)(A).
11 2
 1 U.S.C. § 360j(o)(3)(B) and (C).
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